AbbVie (ABBV) Gains from Sales and Divestitures (2013 - 2016)

AbbVie has disclosed Gains from Sales and Divestitures across 4 years of filings, most recently posting $6.1 million for Q2 2016.

• In Q2 2016, Gains from Sales and Divestitures rose 11.16% year-over-year to $6.1 million; the TTM figure through Jun 2016 stood at $6.1 million (up 11.16% YoY), while the FY2015 annual figure was $5.7 million, down 14.1% from the prior year.
• Gains from Sales and Divestitures rose to $6.1 million in Q2 2016, from $5.5 million in the prior quarter.
• Over the last five years, Gains from Sales and Divestitures for ABBV reached as high as $7.6 million in Q4 2013 and fell as low as $5.3 million in Q1 2015.
• The 4-year median for Gains from Sales and Divestitures is $6.3 million (2014), against an average of $6.4 million.
• Annual changes were most pronounced in 2015 — Gains from Sales and Divestitures dropped 14.53% — and 2016, when it gained 11.16%.
• A 4-year view of Gains from Sales and Divestitures shows it stood at $7.6 million in 2013, then decreased by 12.11% to $6.6 million in 2014, then decreased by 14.1% to $5.7 million in 2015, then advanced by 7.65% to $6.1 million in 2016.
• According to Business Quant data, Gains from Sales and Divestitures over the past three periods registered $6.1 million, $5.5 million, and $5.7 million for Q2 2016, Q1 2016, and Q4 2015 respectively.